Managed entry agreements and funding for expensive therapies / Mondher Toumi, Szymon Jaroslawski.

Author/creator Toumi, Mondher
Other author Jaroslawski, Szymon.
Format Electronic
EditionFirst edition.
Publication InfoBoca Raton : CRC Press, 2022.
Descriptionpages cm.
Supplemental ContentFull text available from Taylor & Francis eBooks
Subjects

SeriesPharmaceuticals, health economics and market access
Contents Introduction to managed entry agreements -- From coverage with evidence development to individual performance-based agreements in Italy -- Coverage with evidence development for multiple sclerosis drugs in the UK--a "costly failure"? -- Novel funding models for expensive therapies -- Definition and classification of MEAs -- Country comparison of the implementation of managed entry agreements.
Abstract "Managed Entry Agreements and Funding for Expensive Therapies examines the concept of MEA, detailing how depreciation of some specific therapies through intangible amortization is unavoidable"-- Provided by publisher.
Bibliography noteIncludes bibliographical references and index.
Access restrictionAvailable only to authorized users.
Technical detailsMode of access: World Wide Web
Genre/formElectronic books.
LCCN 2021059395
ISBN9780367500269 (paperback)
ISBN9780367500290 (hardback)
ISBN(ebook)

Availability

Library Location Call Number Status Item Actions
Electronic Resources Access Content Online ✔ Available